Company / Revenue per Share
Inhibrx Biosciences, Inc. Revenue per Share History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.09
FY2025
5-year range
$0.04 / $0.15
FY2023-FY2025
Trend
+136.3%
vs FY2024
Sector context
#135 of 154
Health Care
What the data says
Inhibrx Biosciences, Inc.'s revenue per share of $0.09 is lower than 88% of companies in the Health Care sector (FY2025). Declined from $0.15 to $0.09 over the past 2 years.
Based on SEC 10-K filings.
0.09 in FY2025.
Declined from $0.15 to $0.09 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 154This company $0.09 Sector average $15.09
▼
-99.4% below sector average
Key checks
Key Insights
- In FY2025, revenue per share increased 136.3% year-over-year.
- Ranks #135 out of 154 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.09 | +136.3% |
| FY2024 | $0.04 | -75.1% |
| FY2023 | $0.15 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026